REGULATION AND LEGISLATION
BUSINESS AND INVESTMENT
Clarmin to acquire psychedelics firm Cybin in reverse takeover.
Core One Labs completes acquisition of interest in Rejuva and Shahcor medical clinics.
ATAI Life Sciences acquires Kures to develop novel therapeutics for opioid abuse.
Mydecine Innovations signs definitive agreement to acquire Neuropharm.
RESEARCH AND SCIENCE
THE PSYCHEDELICS AS MEDICINE REPORT
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
|PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.|
The psychedelics industry is championing digital health. Pioneers and early movers in the psychedelics industry are using technology to develop bespoke therapies for patients and to open access to healthcare for greater numbers of patients via telehealth services. Read our analysis here.